Europe Label Free Detection Market Analysis, Size, and Share by 2028

The Europe label free detection market is expected to reach US$ 236.30 million by 2028 from US$ 137.27 million in 2021; it is estimated to grow at a CAGR of 8.1% from 2021 to 2028.

The growth of the market is attributed to rising pharmaceutical outsourcing across Europe, and the growing number of drug discovery programs through academic–industrial partnerships. However, the lack of skilled professionals limits the market growth.

The practice of outsourcing biotechnology and pharmaceutical services is becoming more popular due to the effects of the COVID-19 pandemic, and the rise in drug development costs and R&D investments. Pharmaceutical companies are increasingly outsourcing research activities to academic and private contract research organizations (CROs) to stay competitive and flexible in the world of exponentially growing knowledge, increasingly sophisticated technologies, and an unstable financial environment.

•          AstraZeneca is in the process of shifting its global headquarters to Cambridge, UK, to harness the university’s scientific knowledge. In 2013–2014, the company established several strategic R&D outsourcing partnerships with academic organizations, along with the Academic Drug Discovery Consortium (ADDC), the Medical Research Council Laboratory of Molecular Biology (MRC LMB), and the Cancer Research UK (CRUK) Cambridge Institute.

Therefore, rise in pharmaceutical outsourcing would fuel the growth of the label free detection market.  

Further, direct partnerships of pharmaceutical and biotechnology companies with academic centers are becoming prevalent. For academic and pharmaceutical researchers, the benefits of these partnerships are evident. Financial support from pharmaceutical companies provides steady funding and increases the probability of impactful work. These collaborations may begin with funding for academic research for promising candidates. The strategy helps pharmaceutical companies fill gaps in their portfolios at lower costs and risks. The growing number of such drug discovery programs through academic–industrial partnerships propels the growth of the label free detection market.

Europe Label Free Detection MarketRevenue and Forecast to 2028 (US$ Million)

EUROPE LABEL FREE DETECTION MARKET SEGMENTATION

The Europe label free detection market based on the product is segmented into instruments and consumables. Based on technology, the Europe label free detection market is segmented into surface plasmon resonance, bio-layer interferometry, isothermal titration calorimetry, differential scanning calorimetry, and other LFD technologies. The Europe label free detection market, based on application is segmented into binding kinetics, binding thermodynamics, endogenous receptor detection, hit confirmation, lead generation, and other applications. The Europe label free detection market, based on end user is segmented into pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations and other end users. Geographically, the Europe label free detection market can be divided into Germany, Italy, Spain, UK, France and Rest of Europe.

General Electric, Perkin Elmer, Inc., AMETEK Inc., F. HOFFMANN-LA ROCHE LTD., Spectris, METTLER TOLEDO, Agilent Technologies, Inc., Waters Corporation, Sartorius AG and Corning Incorporated are among the leading companies operating in the Europe label free detection market.

Europe Label Free Detection Report Scope